Concert Pharmaceuticals Inc (NASDAQ:CNCE)
| 6.86 Delayed Data As of 3:59pm ET |  +0.24 / +3.63%Today’s Change | 2.57 Today|||52-Week Range 7.34 | +117.78% Year-to-Date |
Latest CNCE News | Press Releases
| What Makes Concert (CNCE) a Good Fit for "Trend Investing" Aug 05 / Zacks.com - Paid Partner Content | Concert Pharmaceuticals (CNCE) Reports Q2 Loss, Lags Revenue Estimates Aug 04 / Zacks.com - Paid Partner Content |
| Does Concert (CNCE) Have the Potential to Rally 158% as Wall Street Analysts Expect? Aug 04 / Zacks.com - Paid Partner Content | Rigel Pharmaceuticals (RIGL) Reports Q2 Loss, Tops Revenue Estimates Aug 02 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 6.62 |
| Today’s open | 6.62 |
| Day’s range | 6.47 - 7.32 |
| Volume | 71,405 |
| Average volume (3 months) | 690,127 |
| Market cap | $284.8M |
Data as of 3:59pm ET, 08/09/2022
Growth & Valuation
| Earnings growth (last year) | +2.91% |
| Earnings growth (this year) | -18.56% |
| Earnings growth (next 5 years) | +10.90% |
| Revenue growth (last year) | +312.28% |
| P/E ratio | NM |
| Price/Sales | 3.33 |
| Price/Book | 1.90 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| --China Health Group I... | 0.00 | 0.00% |
| FULCFulcrum Therapeutics... | -0.28 | -3.65% |
| --Photocure ASA | 0.00 | 0.00% |
| EVLOEvelo Biosciences In... | -0.31 | -10.30% |
Data as of 3:59pm ET, 08/09/2022
Financials
| Next reporting date | November 10, 2022 |
| EPS forecast (this quarter) | -$0.59 |
| Annual revenue (last year) | $32.6M |
| Annual profit (last year) | -$80.1M |
| Net profit margin | -245.72% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Lexington, Massachusetts |
Forecasts
